The underwhelming response of CRC to selective BRAF inhibitors along with the paradoxical activation of such selective BRAF inhibitors in a RASmut setting underscores the need for novel approaches to abrogate signaling through the RAF/MEK/ERK pathway in KRASmut CRC. This evidence concerns the gene BRAF and colorectal carcinoma.